Lattice Biologics Ltd.
Lattice Biologics Ltd. (LBLTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lbltf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lattice Biologics Ltd.You LBLTF | $0M | N/A | — | — |
 Allergy Therapeutics plc AGYTF | $655M | N/A | — | -$0.01 |
 Avon Technologies Plc AVNBF | $627M | 78.12x | +76.6% | $0.36 |
 Beijing Tong Ren Tang Chinese Medicine Company Limited BJTRF | $536M | 10.64x | -76.0% | $0.47 |
 PolyNovo Limited CALZF | $415M | 64.01x | +44.7% | $0.02 |
 CellaVision AB (publ) CLVSF | $322M | 24.18x | -45.4% | $6.42 |
 Euroapi S.A. EAPIF | $163M | N/A | — | -$2.23 |
Industry Average 4 peers with valid PE | — | 44.24x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lattice Biologics Ltd. (LBLTF) measures how much investors pay for each dollar of the company's trailing earnings. LBLTF's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
LBLTF pe ratio · 6 questionsLBLTF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via LBLTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lattice Biologics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09